The Billion-Dollar Race for a Totally Implantable Cochlear Implant [Updated]

By Khue Do in Singapore
Last updated: October 6, 2026

Cochlear has spent many years establishing itself in the leading position among hearing implant providers. Its revenue is more than two and a half times that of MED-EL, the next-largest company in the space.

Yet a new technology may offer Cochlear’s smaller rivals an opportunity to challenge the company. MED-EL, Envoy Medical, and Cochlear are all developing totally implantable cochlear implants, or TICIs. A TICI would provide hearing assistance without any external sound processor.

In September 2026, MED-EL rolled out the first commercial TICI product: its TICI UNICO is now available in Europe.

But launching first is only one step. No TICI is approved in the United States, the largest cochlear implant market, and MED-EL has not given a timeline for FDA approval. Envoy has finished enrolling patients in its U.S. pivotal trial and has started its filing process with the FDA. Cochlear has completed recruitment in its pivotal trials in Australia, France and the U.S.

Cochlear wants to prevent competitors from undermining its market leadership. If MED-EL or Envoy can convert their head start into adoption before Cochlear brings its own device to market, they could capture a bigger piece of the current cochlear implant market.

Hearing implant manufacturer revenue ranking: Cochlear US$1,510 million; MED-EL US$578 million; Advanced Bionics US$303 million; Oticon Medical estimated US$80–100 million; Nurotron US$35 million; Shanghai Listent US$11 million.

Read the full ranking: The World’s Leading Hearing Implant Manufacturers in 2026.

Why Totally Implantable Implants Matter

Traditional cochlear implants have an electrode and receiver placed inside the user’s body. However, they still require an external microphone and processor. These must be removed when showering, swimming and often sleeping.

By moving these components inside the body, TICI technology would allow users to hear even while sleeping, showering or swimming, with no externally visible devices, depending on the eventual product and approved uses.

The concept is simple enough. But implementation has been challenging, and it has taken many years to bring to fruition.

A variety of elements must be addressed when a microphone is implanted under the skin:

  • It must pick up speech through skin and tissue while filtering out sounds from breathing, chewing and movement.
  • Power must be available to run the system all day. The battery must be safely rechargeable through the skin and last for many years.
  • An external processor that fails is relatively easy to replace. Implanted devices that fail may require another procedure.

Not only must the device provide good hearing, but it must do so for many years.

MED-EL: First to Market

MED-EL has arguably produced the strongest published evidence so far that a fully implanted system can deliver hearing comparable with a conventional cochlear implant.

Its first human study implanted six adults with its Mi2000 TICI product beginning in 2020. Participants were followed for 52 weeks and tested both with the implanted microphone and processor and with an external MED-EL processor connected to the same implant, comparing the results.

The peer-reviewed feasibility study found that speech performance in quiet and noise was broadly comparable between the two configurations. Five of the six participants used the completely implanted mode for the majority of their listening time. One participant experienced swelling and apparent infection at the implant site, which was successfully treated.

Although these results are encouraging, the study had only six patients — too few to evaluate the safety and longevity of this new implant.

MED-EL has since moved to a pivotal study. Its pivotal Mi2000 study enrolled 30 hearing-impaired adults across Europe and tested how well patients wearing implants could recognize words six months after being fitted compared to their pre-op results.

The study, the most mature pivotal study on the topic so far, was completed in September 2025. As of early October 2026, the results had not been published; MED-EL says they have been submitted to a journal.

MED-EL did not wait for publication to launch. On September 29, 2026, the company introduced TICI UNICO, which it describes as the world’s first commercially available totally implantable cochlear implant. The device received its European CE mark in July 2026 and is now available in Europe, including France. At launch, MED-EL said 40 people had received the implant.

TICI UNICO is authorized for adults with severe-to-profound sensorineural hearing loss. Its implanted battery provides up to 40 hours of use per charge and is recharged through the skin with an external accessory placed on the head, taking roughly an hour a day. The battery is not separately replaceable — if replacement becomes necessary, it requires revision surgery to exchange the implant.

The launch is a milestone, but a European one. TICI UNICO is not approved in the United States, and MED-EL has not estimated when FDA authorization might come. Reimbursement arrangements are also still being pursued in many countries.

MED-EL has the infrastructure to turn the launch into real share. The privately owned Austrian manufacturer says its products are used by more than 5,600 clinics across 142 countries and that it invests 15-20% of turnover in research and development, according to its company profile.

A successful TICI would give an established global manufacturer a potentially important new way to take share from Cochlear.

Envoy: The Highest-Risk Attempt to Break into the Market

Envoy Medical is making the larger bet. The company’s SEC filings describe Acclaim as its principal development opportunity, meaning success or delay carries far greater consequences for Envoy than for either MED-EL or Cochlear.

Acclaim takes a different approach to the implanted-microphone problem. Instead of placing a conventional microphone under the skin, it uses a piezoelectric sensor attached to the middle ear.

It is designed to use the body’s innate mechanism for capturing sound. The sensor is similar to the one Envoy used in its Esteem middle-ear implant.

That could help avoid some of the acoustic problems associated with subcutaneous microphones, but it introduces its own mechanical and surgical requirements.

Envoy’s product features replaceable batteries with an estimated lifespan of eight to 12 years, according to its SEC filings. However, that figure is still only a design expectation. The company has not yet demonstrated this capability in a clinical setting.

In March 2026, Envoy finished enrolling its pivotal U.S. study of 56 patients. Patients are being assessed for word recognition 12 months after implantation compared to their baseline aided hearing prior to surgery.

Among the first 10 participants to reach 12 months, mean CNC (consonant-nucleus-consonant) word-recognition scores increased from 15.2% before implantation to 53.2% at 12 months, according to the company. That was also an improvement from a mean 39.2% at six months. Envoy reported the 12-month data in July 2026.

However, 10 patients are less than one-fifth of the pivotal study group. These are preliminary company findings, not the final trial results.

Still, Envoy is the furthest along of the three on a publicly disclosed U.S. regulatory pathway toward FDA approval. The first of its four planned PMA (premarket approval) modules was sent to the FDA in 2026. Submission of the fourth module, containing all final trial data, is expected in the second quarter of 2027.

Acclaim has also received FDA Breakthrough Device designation, which can enable closer interaction with the regulator but does not lower the standard required for approval. Envoy detailed its PMA progress in its second-quarter 2026 update.

Approval would also create an entirely new set of challenges for the company: Envoy does its final assembly in Minnesota, but it depends on external companies for many critical subcomponents, some of which have only a single supplier, according to the company’s 2025 annual report.

This could make it difficult for Envoy to scale Acclaim up to full production. It would have to build much of the production and commercial infrastructure that its competitors already possess.

Cochlear Is Now Closing the Gap

As the largest and most established of the three competing companies, Cochlear’s situation is more defensive: It does not need TICI to create a cochlear implant business. It needs TICI to protect the business and market share it already has.

Its scale gives Cochlear substantial advantages in production, regulatory affairs, surgical training, fitting software, clinical relationships and long-term recipient support.

Until recently Cochlear’s TICI program appeared to trail its competitors on some key clinical milestones.

But that gap is narrowing. Cochlear now has two pivotal studies underway and a smaller supporting study.

Cochlear’s ENTERPRISE pivotal study is testing a totally implantable system in 36 adults in Australia and France. The study is active but no longer recruiting.

More significantly, Cochlear began a separate U.S. pivotal study called ELEVATE in April 2026, enrolling 56 adults across 11 U.S. sites to test Cochlear’s TI1132 implant. Primary completion is currently expected in October 2027.

In September 2026, Cochlear announced that recruitment across its worldwide trial program was complete, with 92 adults enrolled across the two pivotal studies. The company also said its fully implantable technology program has surpassed one million hours of patient experience, with more than 100 recipients across three generations of investigational devices dating back to 2005.

The investigational system uses an implanted microphone beneath the skin, allowing patients to hear without an external processor.

Cochlear is also running the smaller ENHANCE study, focused specifically on implanted-microphone performance and signal processing.

The implanted microphone is one of the toughest engineering hurdles to overcome. Cochlear’s own earlier research found that bodily sounds such as breathing and swallowing could interfere with usable sound. Cochlear’s continued focus on how the microphone behaves after implantation suggests the company still treats this as a significant hurdle.

The company may therefore arrive later than Envoy in the U.S. regulatory process. But unlike Envoy, Cochlear can afford to wait. MED-EL has now rolled out its TICI solution first, and analysts at Macquarie estimate Cochlear is about a year behind. But Cochlear can still bring its own device to market and sell it through its pre-existing global commercial system.

Why Being First May Not Be Enough

Displacing traditional implant technology, even with a better alternative, isn’t like getting people to switch phone plans or even hearing aids. There are significant barriers to entry.

For example, surgeons become comfortable with a certain electrode array and system. Audiologists are already trained on a manufacturer’s platform. Many clinics have already built their entire process and workflow around one manufacturer.

Recipients may depend on a manufacturer for processor upgrades, software and servicing for decades. Even when a smaller company gains approval and fields a strong product, it may be difficult to get providers to disrupt their business models to make the switch.

TICI adds further considerations:

  • Patients with conventional implants and external processors can easily upgrade to a new processor today, just by swapping the component. A totally implantable device will need some other method for upgrading that does not require repeated surgery.
  • Internal batteries will age, and replacing them requires a procedure.
  • Microphones or sensors must keep functioning even as tissue grows around them.

This situation naturally favors companies with a long track record of dependable implants and a well-developed service network. But it also allows challengers to enter the fray if their technology is notably superior.

For Envoy, an approved system that eliminates the conventional implanted microphone could provide a clear point of differentiation. For MED-EL, a launched product combined with its existing global footprint could make TICI a more credible competitive weapon than a conventional product refresh.

CompanyCommercial positionLatest clinical and regulatory progressNext hurdle
MED-ELTICI UNICO available in Europe; no U.S. approvalEuropean pivotal study completed in September 2025; results submitted to a journalReimbursement, wider adoption and an undisclosed U.S. timeline
Envoy MedicalAcclaim remains investigational56-patient U.S. pivotal trial fully enrolled; first PMA module submitted in 2026Final trial results; fourth PMA module expected in Q2 2027; commercial scale-up
CochlearTotally implantable system remains investigational92 adults enrolled across ENTERPRISE and ELEVATE; worldwide pivotal recruitment completeELEVATE primary completion expected in October 2027; approval and market entry

SANOR’s comparison of MED-EL, Envoy Medical and Cochlear in the race for a totally implantable cochlear implant, October 2026.

The Bigger Prize Is Market Share

There is no billion-dollar TICI market today. TICI UNICO has only just reached its first patients. The billion-dollar opportunity comes from the cochlear implant market the technology could reshape.

Cochlear alone generated A$2.34 billion (≈ US$1.51 billion) in FY2026 revenue across its hearing-implant systems, products and services, according to its FY2026 results.

If TICI becomes an important product category, the first effect could simply be redistribution. Patients who would otherwise have received a traditional cochlear implant may choose MED-EL or Envoy instead of Cochlear because they prefer a totally implantable system. That is, TICI technology mostly replaces the older technology, but does not reach any big new customer segments.

The more ambitious possibility is that TICI expands the entire implant market itself.

Many more people could benefit from cochlear implants than currently use them. The authors of MED-EL’s feasibility study note that tens of millions of people worldwide have severe-to-profound hearing loss, but only a small fraction of them have received implants.

A totally implantable system isn’t enough to bridge that gap on its own. The process involves surgery, cost and reimbursement, patient education, and suitability assessments.

But if a TICI can eliminate visible external hardware, require less daily upkeep, and provide uninterrupted hearing, it might encourage more people to opt for implantation.

If that occurs, the competition will escalate beyond poaching patients from Cochlear. The companies will be competing to expand the overall market.

Who Is Ahead?

For the first time, one measure has a clear answer: MED-EL is first to market. TICI UNICO is commercially available in Europe, and no competitor has an approved product anywhere. Macquarie analysts see the launch as a near-term risk to Cochlear’s market share among new adult cochlear implant recipients in European markets.

MED-EL’s lead has limits, though. It is confined to Europe, its pivotal trial data remains unpublished, and reimbursement is still being negotiated in many countries. First to market is not yet the same as winning the market.

Envoy remains furthest ahead on the path to FDA approval in the U.S. — and MED-EL’s silence on its own U.S. timeline leaves Envoy a window to be first in the market that matters most commercially. But Envoy still has to prove its results across the full cohort, and then build a commercial organization capable of competing with much larger manufacturers.

Cochlear is now the only one of the three without a launched or FDA-filed product. Its enrollment-complete pivotal program shows it is moving, and if its product proves competitive, its manufacturing scale and extensive clinic and support infrastructure would be difficult for any competitor to overcome.

The question has shifted from who will be first to whether MED-EL — and potentially Envoy in the U.S. — can turn their head start into enough surgeon and patient adoption to hold share once Cochlear enters.

That is where the billion-dollar race will actually be won.

Next read: The World’s Leading Hearing Implant Manufacturers in 2026

Sanor publishes for general information. This publication is not medical, financial, or investment advice.

Privacy Policy Terms of Service Disclaimer Sitemap

SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.

SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.

All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.